THE SUBTYPES OF PANCREATIC DUCTALADENOCARCINOMAS

Being the 4th leading cause of cancer deaths
in the U.S. and with a global increase in incidence,
above 80% of pancreatic cancers are locally advanced
or metastatic at the time of diagnosis. As surgical resection
is the only hope for a cure, the answer is probably
in early screening, proper classification and right
therapy. The advancing research will likely lead to a
better understanding of Pancreatic Ductal Adenocarcinoma
(PDAC) as well as enhance the techniques for
screening, diagnosis, accurate subtyping and enable
the use of targeted therapy. Thus, instead of clubbing
together various subtypes of PDAC for trials, improving
the subcategorization will ensure statistical significance
for the academicians, and the clinicians would
avoid administration of placebo drug to a vast number
of patients.